Literature DB >> 19450180

Role of the MTHFR polymorphisms in cancer risk modification and treatment.

Young-In Kim1.   

Abstract

The role of folate, a water-soluble B vitamin, and single nucleotide polymorphisms (SNPs) in the folate metabolic pathway in human health and disease has been rapidly expanding. Recently, functionally significant SNPs in 5,10-methylenetetrahydrofolate reductase (MTHFR), a critical enzyme for intracellular folate homeostasis and metabolism, have been identified and characterized. The MTHFR SNPs are ideal candidates for investigating the role of SNPs in cancer risk modification and treatment because of their well-defined and highly relevant biochemical effects on intracellular folate composition and one-carbon transfer reactions. Indeed, a large body of molecular epidemiologic evidence suggests that the MTHFR 677 variant T allele is associated with cancer risk in a site-specific manner. Furthermore, biologically plausible mechanisms based on the functional consequences of changes in intracellular folate cofactors resulting from the MTHFR 677T variant exist to readily explain cancer risk modification associated with this variant. In addition, a growing body of in vitro and clinical evidence suggests that the MTHFR SNPs may be an important pharmacogenetic determinant of response to and toxicity of 5-fluorouracil (5FU) and methotrexate (MTX)-based cancer and anti-inflammatory chemotherapy. Furthermore, studies suggest that MTHFR inhibition may be a potential target for increasing chemosensitvity of cancer cells to 5FU-based chemotherapy. Because the MTHFR SNPs are prevalent and MTX and 5FU are widely used for the treatment of common cancers and inflammatory conditions, the pharmacogenetic role of the MTHFR SNPs has significant clinical implications. MTHFR SNPs may play an important role in providing rational, effective and safe tailored treatment to patients with cancer and inflammatory disorders requiring 5FU and MTX-based therapy. As such, largescale human studies and in vitro mechanistic studies are warranted to clarify the pharmacogenetic role of the MTHFR SNPs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19450180     DOI: 10.2217/fon.09.26

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  18 in total

1.  Associations of the MTHFR rs1801133 polymorphism with gastric cancer risk in the Chinese Han population.

Authors:  Zhiqiang Han; Huaming Sheng; Qiuzhi Gao; Yu Fan; Xiang Xie
Journal:  Biomed Rep       Date:  2020-11-17

2.  Associations between methylenetetrahydrofolate reductase polymorphisms and hepatocellular carcinoma risk in Chinese population.

Authors:  Xiaosheng Qi; Xing Sun; Junming Xu; Zhaowen Wang; Jinyan Zhang; Zhihai Peng
Journal:  Tumour Biol       Date:  2014-01-03

3.  MTHFR C677T and A1298C polymorphisms and cervical carcinoma susceptibility: meta-analyses based on 4,421 individuals.

Authors:  Wen-Lei Zhuo; Liang Zhang; Jun-Jun Ling; Yi Zhu; Zheng-Tang Chen
Journal:  Mol Biol Rep       Date:  2012-06-19       Impact factor: 2.316

4.  Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.

Authors:  Barbara Faganel Kotnik; Iztok Grabnar; Petra Bohanec Grabar; Vita Dolžan; Janez Jazbec
Journal:  Eur J Clin Pharmacol       Date:  2011-04-21       Impact factor: 2.953

5.  Reality check: there is no such thing as a miracle food.

Authors:  Maki Inoue-Choi; Sarah J Oppeneer; Kim Robien
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

6.  The polymorphism of methylenetetrahydrofolate reductase C677T but not A1298C contributes to gastric cancer.

Authors:  Long Lv; Ping Wang; Beicheng Sun; Gong Chen
Journal:  Tumour Biol       Date:  2013-07-30

7.  Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.

Authors:  Xiaoying Li; Minhua Shao; Shiming Wang; Xueying Zhao; Hongyan Chen; Ji Qian; Xiao Song; Jiucun Wang; Li Jin; Junjie Wu; Qiang Li; Chunxue Bai; Baohui Han; Zhiqiang Gao; Daru Lu
Journal:  Tumour Biol       Date:  2014-08-08

8.  MTHFR gene polymorphism in acute lymphoblastic leukemia among North Indian children: a case-control study and meta-analysis updated from 2011.

Authors:  Nirmalya Roy Moulik; Farah Parveen; Archana Kumar; Shally Awasthi; Suraksha Agrawal
Journal:  J Hum Genet       Date:  2014-06-12       Impact factor: 3.172

9.  Association between Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to cervical cancer: a meta-analysis.

Authors:  Lili Yu; Kai Chang; Jian Han; Shaoli Deng; Ming Chen
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

10.  Comprehensive evaluation of one-carbon metabolism pathway gene variants and renal cell cancer risk.

Authors:  Todd M Gibson; Paul Brennan; Summer Han; Sara Karami; David Zaridze; Vladimir Janout; Helen Kollarova; Vladimir Bencko; Marie Navratilova; Neonila Szeszenia-Dabrowska; Dana Mates; Alena Slamova; Ruth M Pfeiffer; Rachael Z Stolzenberg-Solomon; Susan T Mayne; Meredith Yeager; Stephen Chanock; Nat Rothman; Wong-Ho Chow; Philip S Rosenberg; Paolo Boffetta; Lee E Moore
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.